Certain types of leukemia and solid cancer types like small cell lung cancer are highly sensitive to both KDM1A knock-down and inhibition [6–8], and several selective KDM1A inhibitors are in Phase I and II clinical trials for the treatment of hematological or solid tumor indications. This evidence concerns the gene KDM1A and leukemia.